GeneDx is trading 10.19% higher at $61.87, rebounding after its October 23 sell-off; no clear company-specific catalyst for the October 26 move has been identified.
- U.S. indexes are higher and oil prices have eased, supporting broader market sentiment; Reuters described Monday’s global shares as edging up.
- GeneDx’s third-quarter results are scheduled for November 9, but the announcement does not explain today’s move.